The DOI matches its Crossref record; 582 of the 582 references it cites were found in a registry or an index.
Inhibition and induction of human cytochrome P450 enzymes: current status
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 582
Cashman, J. R., Park, S. B., Yang, Z. C., Wrighton, S. A., Jacob, P., & Benowitz, N. L. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00029a008 · Cited by 211
Bidstrup, T. B., Bjørnsdottir, I., Sidelmann, U. G., Thomsen, M. S., & Hansen, K. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01862.x · Cited by 209
Darwish, M., Kirby, M., Robertson, P., & Hellriegel, E. T. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00006 · Cited by 209
Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
Yanagihara, Y., Kariya, S., Ohtani, M., Uchino, K., Aoyama, T., Yamamura, Y., & Iga, T. (2001) · PubMed · Cited by 209
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Ko, J. W., Sukhova, N., Thacker, D. L., Chen, P., & Flockhart, D. A. (1997) · PubMed · Cited by 209
Campbell, M. E., Grant, D. M., Inaba, T., & Kalow, W. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06689-9 · Cited by 208
Stearns, R. A., Chakravarty, P. K., Chen, R., & Chiu, S. H. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06520-1 · Cited by 208
Court, M. H., Duan, S. X., Hesse, L. M., Venkatakrishnan, K., & Greenblatt, D. J. (2001) · Anesthesiology · doi:10.1097/00000542-200101000-00021 · Cited by 207
Svensson, & Ashton (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00044.x · Cited by 205
Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9
Veronese, M. E., Mackenzie, P. I., Doecke, C. J., McManus, M. E., Miners, J. O., & Birkett, D. J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91680-b · Cited by 204
Nakamura, K., Moore, R., Negishi, M., & Sueyoshi, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610072200 · Cited by 203
Human CYP1B1 and Anticancer Agent Metabolism: Mechanism for Tumor-Specific Drug Inactivation?
Rochat, B., Morsman, J. M., Murray, G. I., Figg, W. D., & McLeod, H. L. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38762-2 · Cited by 200
Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmöller, J., Zanger, U. M., & Wojnowski, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404949200 · Cited by 198
In Vitro Approaches to Predicting Drug Interactions In Vivo
von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., Harmatz, J. S., & Shader, R. I. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00239-6 · Cited by 197
Kawajiri, K., & Fujii-Kuriyama, Y. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.03.038 · Cited by 197
Biotransformation of lovastatin
Wang, R. W., Kari, P. H., Lu, A. Y. H., Thomas, P. E., Guengerich, F. P., & Vyas, K. P. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90551-s · Cited by 196
Drugs as CYP3A Probes, Inducers, and Inhibitors
Liu, Y.-T., Hao, H.-P., Liu, C.-X., Wang, G.-J., & Xie, H.-G. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701690374 · Cited by 196
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
Yeh, R. F., Gaver, V. E., Patterson, K. B., Rezk, N. L., Baxter-Meheux, F., Blake, M. J., Eron, J. J., Klein, C. E., Rublein, J. C., & Kashuba, A. D. M. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219774.20174.64 · Cited by 194
Oneta, C. M., Lieber, C. S., Li, J., Rüttimann, S., Schmid, B., Lattmann, J., Rosman, A. S., & Seitz, H. K. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00223-9 · Cited by 194
Inhibition of Coumarin 7-Hydroxylase Activity in Human Liver Microsomes
Draper, A. J., Madan, A., & Parkinson, A. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9964 · Cited by 191
Kobayashi, K., Sueyoshi, T., Inoue, K., Moore, R., & Negishi, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.5.1069 · Cited by 190
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology
Lerche-Langrand, C., & Toutain, H. J. (2000) · Toxicology · doi:10.1016/s0300-483x(00)00316-4 · Cited by 188
Pearce, R., Greenway, D., & Parkinson, A. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90115-d · Cited by 188
Interaction of Cimetidine with Liver Microsomes
Rendić, S., ČSunjić, V., Toso, R., Kajfež, F., & Ruf, H.-H. (1979) · Xenobiotica · doi:10.3109/00498257909042321 · Cited by 188
Squires, E. J., Sueyoshi, T., & Negishi, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407281200 · Cited by 188
Jossé, R., Aninat, C., Glaise, D., Dumont, J., Fessard, V., Morel, F., Poul, J.-M., Guguen-Guillouzo, C., & Guillouzo, A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019901 · Cited by 187
Otton, S. V., Inaba, T., & Kalow, W. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90332-1 · Cited by 186
Projean, D., Baune, B., Farinotti, R., Flinois, J.-P., Beaune, P., Taburet, A.-M., & Ducharme, J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.748 · Cited by 185
Carlson, D. B., & Perdew, G. H. (2002) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.10051 · Cited by 184
Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8
Walsky, R. L., Gaman, E. A., & Obach, R. S. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004270642 · Cited by 184
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation
Anglicheau, D. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg381 · Cited by 184
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181
Nebert, D. W., Zhang, G., & Vesell, E. S. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952864 · Cited by 181
Prueksaritanont, T., Ma, B., & Yu, N. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01833.x · Cited by 180
A Flexible Approach to Induced Fit Docking
Nabuurs, S. B., Wagener, M., & de Vlieg, J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070593p · Cited by 179
Phase I and II enzyme characterization of two sources of HepG2 cell lines
Hewitt, N. J., & Hewitt, P. (2004) · Xenobiotica · doi:10.1080/00498250310001657568 · Cited by 178
Hewitt, N. J., Lecluyse, E. L., & Ferguson, S. S. (2007) · Xenobiotica · doi:10.1080/00498250701534893 · Cited by 178
Olesen, O. V., & Línnet, K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010717 · Cited by 176
Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol: A New Look at an Old Drug
Zhang, H., Cui, D., Wang, B., Han, Y.-H., Balimane, P., Yang, Z., Sinz, M., & Rodrigues, A. D. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746020-00003 · Cited by 174
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
Wen, X., Wang, J.-S., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.631 · Cited by 173
Tissue-specific mRNA Expression Profiles of Human Nuclear Receptor Subfamilies
Nishimura, M., Naito, S., & Yokoi, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.135 · Cited by 173
SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5
Dennison, J. B., Kulanthaivel, P., Barbuch, R. J., Renbarger, J. L., Ehlhardt, W. J., & Hall, S. D. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009902 · Cited by 173
Yamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P., & Shimada, T. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00133-6 · Cited by 172
Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin
Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_157.x · Cited by 172
Ultraviolet-B Exposure of Human Skin Induces Cytochromes P450 1A1 and 1B1
Katiyar, S. K., Mukhtar, H., & Matsui, M. S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00876.x · Cited by 171
The Nuclear Xenobiotic Receptor CAR
Suino, K., Peng, L., Reynolds, R., Li, Y., Cha, J.-Y., Repa, J. J., Kliewer, S. A., & Xu, H. E. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.036 · Cited by 171
Yoshinari, K., Kobayashi, K., Moore, R., Kawamoto, T., & Negishi, M. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00720-8 · Cited by 170
Cytochrome P450 3A and their regulation
Burk, O., & Wojnowski, L. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0815-3 · Cited by 168
Polymorphisms of CYP2A6 and its practical consequences
Raunio, H., Rautio, A., Gullstén, H., & Pelkonen, O. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01500.x · Cited by 167
Self-citationWang, R. W., Newton, D. J., Scheri, T. D., & Lu, A. Y. H. (1997) · PubMed · Cited by 167
Tateishi, T., Krivoruk, Y., Ueng, Y.-F., Wood, A. J. J., Guengerich, F. P., & Wood, M. (1996) · Anesthesia & Analgesia · doi:10.1097/00000539-199601000-00031 · Cited by 167
Ohyama, K., Nakajima, M., Nakamura, S., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15077-5 · Cited by 166
PXR and CAR: Nuclear Receptors which Play a Pivotal Role in Drug Disposition and Chemical Toxicity
Stanley, L. A., Horsburgh, B. C., Ross, J., Scheer, N., & Wolf, C. R. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600786232 · Cited by 166
CYP2E1: Biochemistry, Toxicology, Regulation and Function in Ethanol-Induced Liver Injury
Kessova, I. G., & Cederbaum, A. I. (2003) · Current Molecular Medicine · doi:10.2174/1566524033479609 · Cited by 166
Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2188 · Cited by 166
Reschly, E. J., & Krasowski, M. D. (2006) · Current Drug Metabolism · doi:10.2174/138920006776873526 · Cited by 166
Galteau, M. M., & Shamsa, F. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0690-3 · Cited by 166
Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse
Moriguchi, T., Motohashi, H., Hosoya, T., Nakajima, O., Takahashi, S., Ohsako, S., Aoki, Y., Nishimura, N., Tohyama, C., Fujii-Kuriyama, Y., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1037886100 · Cited by 164
Dahl, M.-L. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163
TURPEINEN, M., TOLONEN, A., UUSITALO, J., JALONEN, J., PELKONEN, O., & LAINE, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.02.010 · Cited by 163
Self-citationIto, K., Ogihara, K., Kanamitsu, S.-I., & Itoh, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.945 · Cited by 163
Back, D., & Tjia, J. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03963.x · Cited by 163
SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST
Walsky, R. L., Obach, R. S., Gaman, E. A., Gleeson, J.-P. R., & Proctor, W. R. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002766 · Cited by 163
Honkakoski, P., Moore, R., Washburn, K. A., & Negishi, M. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.4.597 · Cited by 162
Self-citationAssessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics
Girre, C., Lucas, D., Hispard, E., Menez, C., Dally, S., & Menez, J.-F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90524-x · Cited by 162
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
McCune, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110215 · Cited by 162
Kunze, K. L., Wienkers, L. C., Thummel, K. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07368-4 · Cited by 161
In vitro and pharmacophore insights into CYP3A enzymes
Ekins, S., Stresser, D. M., & Williams, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00049-x · Cited by 161
Rumack, B. H. (2004) · Hepatology · doi:10.1002/hep.20300 · Cited by 161
Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?
Kirchheiner, J., Fuhr, U., & Brockmöller, J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1801 · Cited by 160
Chang, T. K. H., & Waxman, D. J. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600569828 · Cited by 160
Galetin, A., Burt, H., Gibbons, L., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006874 · Cited by 160
A Phase I Study of Indole-3-Carbinol in Women: Tolerability and Effects
Reed, G. A., Peterson, K. S., Smith, H. J., Gray, J. C., Sullivan, D. K., Mayo, M. S., Crowell, J. A., & Hurwitz, A. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0121 · Cited by 159
Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor
Higashi, E., Fukami, T., Itoh, M., Kyo, S., Inoue, M., Yokoi, T., & Nakajima, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016568 · Cited by 159
Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19
Ha-Duong, N.-T., Dijols, S., Macherey, A.-C., Goldstein, J. A., Dansette, P. M., & Mansuy, D. (2001) · Biochemistry · doi:10.1021/bi010254c · Cited by 158
Li, A. P., Gorycki, P. D., Hengstler, J. G., Kedderis, G. L., Koebe, H. G., Rahmani, R., de Sousas, G., Silva, J. M., & Skett, P. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00081-2 · Cited by 158
The mechanism of the interaction between amiodarone and warfarin in humans
Heimark, L. D., Wienkers, L. C., Kunze, K. L., Gibaldi, M., Eddy, A. C., Trager, W. F., O’Reilly, R. A., & Goulart, D. A. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.39 · Cited by 158
Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates
Brown, C. M., Reisfeld, B., & Mayeno, A. N. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530701836662 · Cited by 158
Landi, M. T., Sinha, R., Lang, N. P., & Kadlubar, F. F. (1999) · PubMed · Cited by 157
Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics
Howard, L. A., Miksys, S. L., Hoffmann, E. B., Mash, D. C., & Tyndale, R. F. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705146 · Cited by 156
Ekins, S., Chang, C., Mani, S., Krasowski, M. D., Reschly, E. J., Iyer, M., Kholodovych, V. V., Ai, N., Welsh, W. J., Sinz, M., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038398 · Cited by 156
The Nuclear Xenobiotic Receptor Pregnane X Receptor: Recent Insights and New Challenges
Orans, J., Teotico, D. G., & Redinbo, M. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0156 · Cited by 156
Identification of the cytochrome P450 enzymes involved in the N‐demethylation of sildenafil
Hyland, R., Roe, E. G. H., Jones, B., & Smith, D. A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.00318.x · Cited by 155
A Pharmacophore for Human Pregnane X Receptor Ligands
Ekins, S., & Erickson, J. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.1.96 · Cited by 155
Mammalian cytochromes P450—Importance of tissue specificity
Seliškar, M., & Rozman, D. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.09.016 · Cited by 154
Smith, G. C., Wolf, C. R., Deeni, Y., Dawe, R. S., Evans, A. T., Comrie, M., Ferguson, J., & Ibbotson, S. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13081-4 · Cited by 153
Diczfalusy, U., Miura, J., Roh, H., Mirghani, R. A., Sayi, J., Larsson, H., Bodin, K., Allqvist, A., Jande, M. B., Jong-Wook, K., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f50ee9 · Cited by 152
Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes
Kim, K., Park, J. Y., Lee, J., & Lim, S. (2003) · Archives of Pharmacal Research · doi:10.1007/bf02976712 · Cited by 152
Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
Zand, R., Nelson, S. D., Slattery, J. T., Thummel, K. E., Kalhorn, T. F., Adams, S. P., & Wright, J. M. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.125 · Cited by 152
Luo, G., Guenthner, T. M., Gan, L.-S. L., & Humphreys, W. G. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335397 · Cited by 152
AN ASSESSMENT OF UDP-GLUCURONOSYLTRANSFERASE INDUCTION USING PRIMARY HUMAN HEPATOCYTES
Soars, M. G., Petullo, D. M., Eckstein, J. A., Kasper, S. C., & Wrighton, S. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.140 · Cited by 152
Role of CYP2C9 polymorphism in losartan oxidation.
Yaşar, Ü., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman‐Sundberg, M., Dahl, M. L., & Eliasson, E. (2001) · PubMed · Cited by 151
Rasmussen, B., Mäenpää, J., Pelkonen, O., Loft, S. H., Poulsen, H. E., Lykkesfeldt, J., & Brøsen, K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04422.x · Cited by 151
Self-citationPrediction of Drug Metabolism and Interactions on the Basis of in vitro Investigations
Pelkonen, O., Turpeinen, M., Uusitalo, J., Rautio, A., & Raunio, H. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960305.x · Cited by 151
Self-citationIdentification of a novel dioxin-inducible cytochrome P450
Rivera, S. P., Saarikoski, S. T., & Hankinson, O. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12856-8 · Cited by 149
Zelko, I. N., Sueyoshi, T., Kawamoto, T., Moore, R., & Negishi, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.8.2838-2846.2001 · Cited by 149
Identification of the human P450 enzymes involved in lansoprazole metabolism.
Pearce, R. E., Rodrigues, A. D., Goldstein, J. A., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12938-8 · Cited by 148
Chiba, M., Hensleigh, M., Nishime, J. A., Balani, S. K., & Lin, J. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07348-9 · Cited by 146
Miki, Y., Suzuki, T., Tazawa, C., Blumberg, B., & Sasano, H. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.12.005 · Cited by 145
Wang, L., Zhou, G., Zhu, B. Y., Wu, J., Wang, J., El‐Aty, A. M. A., Li, T., Liu, J., Tian-lun, Y., Wang, D., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.014 · Cited by 145
Ma, X., Shah, Y. M., Cheung, C., Guo, G. L., Feigenbaum, L., Krausz, K. W., Idle, J. R., & Gonzalez, F. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012831 · Cited by 145
Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T., & Ishizaki, T. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38328-x · Cited by 144
Ghanbari, F., Rowland‐Yeo, K., Bloomer, J. C., Clarke, S. E., Lennard, M., Tucker, G. T., & Rostami‐Hodjegan, A. (2006) · Current Drug Metabolism · doi:10.2174/138920006776359293 · Cited by 143
Genetic variation of CYP2A6, smoking, and risk of cancer
London, S. J., Idle, J. R., Daly, A. K., & Coetzee, G. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04984-8 · Cited by 142
Characterization of a Phenobarbital-responsive Enhancer Module in Mouse P450 Cyp2b10 Gene
Honkakoski, P., & Negishi, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14943 · Cited by 142
Self-citationNovel pathways of bile acid metabolism involving CYP3A4
Bodin, K., Lindbom, U., & Diczfalusy, U. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2004.11.003 · Cited by 141
The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450
Kostrubsky, V. E., Ramachandran, V., Venkataramanan, R., Dorko, K., Esplen, J. E., Zhang, S., Sinclair, J. F., Wrighton, S. A., & Strom, S. C. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15238-5 · Cited by 141
Zhang, W., Kilicarslan, T., Tyndale, R. F., & Sellers, E. M. (2001) · PubMed · Cited by 141
Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs, L. L., Peter, R. M., Thompson, S. J., Rettie, A. E., & Trager, W. F. (1997) · PubMed · Cited by 140
Warrington, J. S., Shader, R. I., Moltke, L. L., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15055-6 · Cited by 139
Shimada, T., Yamazaki, H., & Guengerich, F. P. (1996) · Xenobiotica · doi:10.3109/00498259609046718 · Cited by 137
Fontana, R. J., Lown, K. S., Paine, M. F., Fortlage, L., Santella, R. M., Felton, J. S., Knize, M. G., Greenberg, A., & Watkins, P. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70554-8 · Cited by 137
Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay
Turpeinen, M., Uusitalo, J., Jalonen, J. E., & Olavi, P. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.10.006 · Cited by 137
Self-citationKodama, S., Moore, R., Yamamoto, Y., & Negishi, M. (2007) · Biochemical Journal · doi:10.1042/bj20070481 · Cited by 136
Jacobsen, W., Kirchner, G. I., Hallensleben, K., Mancinelli, L., Deters, M., Hackbarth, I., Benet, L. Z., Sewing, K.-F., & Christians, U. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15273-7 · Cited by 134
Pfrunder, A., Gutmann, H., Beglinger, C., & Drewe, J. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2003.tb02434.x · Cited by 134
Thum, T., Erpenbeck, V. J., Moeller, J., Hohlfeld, J. M., Krug, N., & Borlak, J. T. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.8861 · Cited by 134
Tassaneeyakul, W., Veronese, M. E., Birkett, D., Gonzalez, F. J., & Miners, J. O. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90639-e · Cited by 133
Identification of the Human Cytochromes P450 Responsible for Atomoxetine Metabolism
Ring, B. J., Gillespie, J. S., Eckstein, J. A., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.319 · Cited by 133
Function of human cytochrome P450s: Characterization of the orphans
Guengerich, F. P., Wu, Z., & Bartleson, C. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.079 · Cited by 133
Structure of the Murine Constitutive Androstane Receptor Complexed to Androstenol
Li, S., Vincent, J. G., Brunzelle, J. S., Dussault, I., Lin, M., Ianculescu, I., Sherman, M. A., FORMAN, B. M., & Fernandez, E. J. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.11.037 · Cited by 132
Kearney, A. S., Crawford, L. F., Mehta, S. C., & Radebaugh, G. W. (1993) · Pharmaceutical Research · doi:10.1023/a:1018923325359 · Cited by 131
Elkayam, T., Amitay-Shaprut, S., Dvir‐Ginzberg, M., Harel, T., & Cohen, S. (2006) · Tissue Engineering · doi:10.1089/ten.2006.12.1357 · Cited by 130
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
Niemi, M., Backman, J. T., Neuvonen, M., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115822 · Cited by 130
Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake
PERROT, N., Nalpas, B., Yang, C. S., & Beaune, P. H. (1989) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1989.tb00273.x · Cited by 127
Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity
Shadle, C. R., Lee, Y., Majumdar, A. K., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262950 · Cited by 127
Cytochrome P 450 isoforms involved in melatonin metabolism in human liver microsomes
Facciolá, G., Hidestrand, M., von Bahr, C., & Tybring, G. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000245 · Cited by 126
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
Carlile, D. J., Hakooz, N., Bayliss, M. K., & Houston, J. B. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00935.x · Cited by 126
Nagy, S. R., Sanborn, J. R., Hammock, B. D., & Denison, M. S. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.2.200 · Cited by 126
Stürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126
The human genome project and novel aspects of cytochrome 450 research
Ingelman‐Sundberg, M. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.01.030 · Cited by 125
Long, M., Laier, P., Vinggaard, A. M., Andersen, H. R., Lynggaard, J., & Bonefeld‐Jørgensen, E. C. (2003) · Toxicology · doi:10.1016/j.tox.2003.08.001 · Cited by 125
Molecular Mechanism of Nuclear Translocation of an Orphan Nuclear Receptor, SXR
Kawana, K., Ikuta, T., Kobayashi, Y., Gotoh, O., Takeda, K., & Kawajiri, K. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.524 · Cited by 125
Li, T., & Chiang, J. Y. L. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007575 · Cited by 124
Orlando, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.007 · Cited by 123
The Pregnane X Receptor Regulates Gene Expression in a Ligand- and Promoter- Selective Fashion
Masuyama, H., Suwaki, N., Tateishi, Y., Nakatsukasa, H., Segawa, T., & Hiramatsu, Y. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0434 · Cited by 123
Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract
McDonnell, W. M., Scheiman, J. M., & Traber, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91171-y · Cited by 122
Zilly, W., Breimer, D. D., & Richter, E. A. (1975) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614021 · Cited by 122
Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1
Ono, S., Hatanaka, T., Hotta, H., Tsutsui, M., Satoh, T., & Gonzalez, F. J. (1995) · Pharmacogenetics · doi:10.1097/00008571-199506000-00002 · Cited by 121
Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats
Brady, J. F., Xiao, F., Wang, M.-H., Li, Y., Ning, S. M., Gapac, J. M., & Yang, C. S. (1991) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(91)90125-x · Cited by 121
Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women
Pollock, B. G., Wylie, M. E., STACK, J. A., Sorisio, D. A., Thompson, D. S., Kirshner, M. A., Folan, M., & Condifer, K. A. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008560 · Cited by 121
Functional interaction of intestinal CYP3A4 and P‐glycoprotein
Kivistö, K. T., Niemi, M., & Fromm, M. F. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00291.x · Cited by 120
Vickers, A. E. M., Sinclair, J. R., Zollinger, M., Heitz, F., Glänzel, U., Johanson, L., & Fischer, V. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15022-2 · Cited by 120
McLellan, R. A., Drobitch, R. K., Monshouwer, M., & Renton, K. W. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08417-x · Cited by 120
Seidel, S. D., Li, V., Winter, G. M., Rogers, W. J., Martinez, E. I., & Denison, M. S. (2000) · Toxicological Sciences · doi:10.1093/toxsci/55.1.107 · Cited by 120
Signatures of Environmental Exposures Using Peripheral Leukocyte Gene Expression: Tobacco Smoke
Lampe, J. W., Stepaniants, S. B., Mao, M., Radich, J. P., Dai, H. A., Linsley, P. S., Friend, S. H., & Potter, J. D. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.445.13.3 · Cited by 120
FOOD-DRUG INTERACTIONS VIA HUMAN CYTOCHROME P450 3A (CYP3A)
Fujita, K. (2004) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2004.20.4.195 · Cited by 119
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9
Simonsson, U. S. H., Jansson, B., Hai, T. N., Huong, D. X., Tybring, G., & Ashton, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00092-4 · Cited by 119
Kuypers, D. R. J., Claes, K. J., Evenepoel, P., Maes, B., Coosemans, W., Pirenne, J., & Vanrenterghem, Y. F. C. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00005 · Cited by 118
Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism
enp, J. M., Hall, S. D., Ring, B. J., Strom, S. C., & Wrighton, S. A. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00007 · Cited by 118
A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT
Ekins, S., Andreyev, S., Ryabov, A., Kirillov, E., Rakhmatulin, E. A., Sorokina, S. Y., Bugrim, A. E., & Nikolskaya, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008458 · Cited by 117
Interactions Between Antiretrovirals and Antineoplastic Drug Therapy
Antoniou, T., & Tseng, A. L.-I. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00001 · Cited by 117
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
Djordjević, N., Ghotbi, R., Bertilsson, L., Јаnkovic, S., & Aklillu, E. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0438-6 · Cited by 115
Rifampin decreases the plasma concentrations and effects of repaglinide
Niemi, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111183 · Cited by 115
Structures of cytochrome P450 3A4
Scott, E. E., & Halpert, J. R. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.004 · Cited by 114
Interaction of Sodium Warfarin and Rifampin: Studies in Man
O’Reilly, R. A. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-3-337 · Cited by 114
Ourlin, J.-C., Lasserre, F., Pineau, T., Fabre, J. M., Cunha, A. S., Maurel, P., Vilarem, M., & Pascussi, J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0383 · Cited by 114
Koyano, S., Kurose, K., Saito, Y., Ozawa, S., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Nakajima, T., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.149 · Cited by 114
CYP2E1 – Biochemical and Toxicological Aspects and Role in Alcohol-Induced Liver Injury
Cederbaum, A. I. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_6 · Cited by 113
Mechanism-based inactivators as probes of cytochrome P450 structure and function
Kent, U., Jushchhyshyn, M., & Hollenberg, P. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338478 · Cited by 113
Structural Basis of Selective Cytochrome P450 Inhibition
Halpert, J. R. (1995) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.000333 · Cited by 113
Rae, J. M., Soukhova, N. V., Flockhart, D. A., & Desta, Z. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.525 · Cited by 113
Ek, M., Söderdahl, T., Küppers-Munther, B., Edsbagge, J., Andersson, T. B., Björquist, P., Cotgreave, I. A., Jernström, B., Ingelman‐Sundberg, M., & Johansson, I. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.05.009 · Cited by 112
Back, D., Tjia, J. F., Karbwang, J., & Colbert, J. E. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03359.x · Cited by 112
Martin, P., Riley, R., Back, D. J., & Owen, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707601 · Cited by 112
Saarikoski, S. T., Rivera, S. P., Hankinson, O., & Husgafvel‐Pursiainen, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.027 · Cited by 112
Barditch‐Crovo, P., Trapnell, C. B., Ette, E., Zacur, H. A., Coresh, J., ROCCO, L., HENDRIX, C., & Flexner, C. W. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70138-4 · Cited by 111
Brown, C. M., Reisfeld, B., & Mayeno, A. N. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530802309742 · Cited by 111
Involvement of CYP1A2 and CYP3A4 in Lidocaine N-Deethylation and 3-Hydroxylation in Humans
Wang, J.-S., Backman, J. T., Taavitsainen, P., Neuvonen, P. J., & Kivistö, K. T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15170-7 · Cited by 110
Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2.
Shet, M. S., McPhaul, M. J., Fisher, C., Stallings, N. R., & Estabrook, R. W. (1997) · PubMed · Cited by 110
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Plant, N. J. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.09.024 · Cited by 109
Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.
Doecke, C. J., Veronese, M., Pond, S. M., Miners, J. O., Birkett, D., Sansom, L., & McManus, M. E. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05499.x · Cited by 108
SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO
Turpeinen, M., Nieminen, R. M., Juntunen, T., Taavitsainen, P., Raunio, H., & Pelkonen, O. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.626 · Cited by 108
Self-citationCarbamazepine but not Valproate Induces Bupropion Metabolism
Ketter, T. A., Jenkins, J. B., Schroeder, D. H., Pazzaglia, P. J., Marangell, L. B., George, M. S., Callahan, A. M., Hinton, M. L., Chao, J. Y., & Post, R. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199510000-00004 · Cited by 107
Sesardic, D., Pasanen, M., Pelkonen, O., & Boobis, A. R. (1990) · Carcinogenesis · doi:10.1093/carcin/11.7.1183 · Cited by 107
Self-citationExpression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
Kivistö, K. T., Bookjans, G., Fromm, M. F., Griese, E., Münzel, P., & Kroemer, H. K. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.42615.x · Cited by 106
Lillibridge, J. H., Liang, B. H., Kerr, B. M., Webber, S., Quart, B. D., Shetty, B. V., & Lee, C. A. (1998) · PubMed · Cited by 106
Theophylline metabolism in human liver microsomes: inhibition studies.
Tjia, J., Colbert, J. E., & Back, D. J. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12414-2 · Cited by 104
Park, B. K., Kitteringham, N. R., Pirmohamed, M., & Tucker, G. T. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.03482.x · Cited by 104
Jae Wook Ko, Desta, Z., Soukhova, N. V., et al. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00175.x · Cited by 103
Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin
Härtter, S., Wang, X., Weigmann, H., Friedberg, T., Arand, M., Oesch, F., & Hiemke, C. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00008 · Cited by 103
Niemi, M., Backman, J. T., & Neuvonen, P. J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.001 · Cited by 103
Tassaneeyakul, W., Mohamed, Z., Birkett, D., McManus, M. E., Veronese, M. E., Tukey, R. H., Quattrochi, L. C., Gonzalez, F. J., & Miners, J. O. (1992) · Pharmacogenetics · doi:10.1097/00008571-199208000-00004 · Cited by 103
Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers.
El-Sankary, W., Gibson, G. G., Ayrton, A. D., & Plant, N. J. (2001) · PubMed · Cited by 103
Liu, C., Russell, R. M., & Wang, X. (2003) · Journal of Nutrition · doi:10.1093/jn/133.1.173 · Cited by 102
Hariparsad, N., Carr, B., Evers, R., & Chu, X. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020677 · Cited by 102
Alprazolam Metabolism in vitro: Studies of Human, Monkey, Mouse, and Rat Liver Microsomes
Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (2008) · Pharmacology · doi:10.1159/000139107 · Cited by 100
Rencurel, F., Stenhouse, A., Hawley, S. A., Friedberg, T., Hardie, D. G., Sutherland, C. D., & Wolf, C. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412711200 · Cited by 100
Ekins, S., Mirny, L. A., & Schuetz, E. G. (2002) · Pharmaceutical Research · doi:10.1023/a:1021429105173 · Cited by 99
Involvement of human liver cytochrome P4502B6in the metabolism of propofol
Oda, Y., Hamaoka, N., Hiroi, T., Imaoka, S., Hase, I., TANAKA, K. A., Funae, Y., Ishizaki, T., & Asada, A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.00344.x · Cited by 99
Effect of phenobarbital on theophylline disposition
LANDAY, R., Gonzalez, M. A., & Taylor, J. C. (1978) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(78)90068-4 · Cited by 99
Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine
Fang, J., Coutts, R. T., McKenna, K. F., & Baker, G. B. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005298 · Cited by 99
Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro
Granfors, M. T., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02028.x · Cited by 98
Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects
Park, J. Y., Kim, K., Kang, M., et al. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.003 · Cited by 98
Xue, Y., Moore, L. B., Orans, J., Peng, L., Bencharit, S., Kliewer, S. A., & Redinbo, M. R. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0323 · Cited by 98
Loboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
“It is mostly transcriptional regulation, and mainly resulting from epigenetic regulation, although non-transcriptional mechanisms, such as enzyme stabilization, stabilization of mRNA, or inhibition of protein degradation, have also been reported [94].”
BackgroundAlternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
Self-citationEsteves, F., Rueff, J., & Kranendonk, M. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030007 · Cited by 512
Biotransformation of Xenobiotics
Timbrell, J. A., & Marrs, T. C. (2009) · General, Applied and Systems Toxicology · doi:10.1002/9780470744307.gat004 · Cited by 435
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Self-citation
Metadata
- Authors
- Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H.
- Venue
- Archives of Toxicology
- Published
- 2008-07-11
- Volume
- 82
- Issue
- 10
- Pages
- 667-715
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W2034400329
- Cited by
- 569
- References
- 582
- FWCI
- 36.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.